Published in

Rockefeller University Press, Journal of Cell Biology, 4(202), p. 717-717, 2013

DOI: 10.1083/jcb.20120512508022013c

Rockefeller University Press, Journal of Cell Biology, 7(201), p. 997-1012, 2013

DOI: 10.1083/jcb.201205125

Links

Tools

Export citation

Search in Google Scholar

The tumor suppressor CDKN3 controls mitosis

Journal article published in 2013 by Grzegorz Nalepa ORCID, Jill Barnholtz-Sloan ORCID, Rikki Enzor, Dilip Dey, Ying He, Jeff R. Gehlhausen, Amalia S. Lehmann, Su-Jung Park, Yanzhu Yang, Xianlin Yang, Shi Chen, Xiaowei Guan, Yanwen Chen, Jamie Renbarger, Feng-Chun Yang and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Mitosis is controlled by a network of kinases and phosphatases. We screened a library of small interfering RNAs against a genome-wide set of phosphatases to comprehensively evaluate the role of human phosphatases in mitosis. We found four candidate spindle checkpoint phosphatases, including the tumor suppressor CDKN3. We show that CDKN3 is essential for normal mitosis and G1/S transition. We demonstrate that subcellular localization of CDKN3 changes throughout the cell cycle. We show that CDKN3 dephosphorylates threonine-161 of CDC2 during mitotic exit and we visualize CDC2(pThr-161) at kinetochores and centrosomes in early mitosis. We performed a phosphokinome-wide mass spectrometry screen to find effectors of the CDKN3-CDC2 signaling axis. We found that one of the identified downstream phosphotargets, CKβ phosphorylated at serine 209, localizes to mitotic centrosomes and controls the spindle checkpoint. Finally, we show that CDKN3 protein is down-regulated in brain tumors. Our findings indicate that CDKN3 controls mitosis through the CDC2 signaling axis. These results have implications for targeted anticancer therapeutics.